[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 32 of about 32
1. Chen CW, Wang WM, Su YC, Wu JY, Hsieh JS, Wang JY: Oxaliplatin/5-fluorouracil/leucovorin (FOLFOX4) regimen as an adjuvant chemotherapy in the treatment of advanced jejunal adenocarcinoma: a report of 2 cases. Med Princ Pract; 2008;17(6):496-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxaliplatin/5-fluorouracil/leucovorin (FOLFOX4) regimen as an adjuvant chemotherapy in the treatment of advanced jejunal adenocarcinoma: a report of 2 cases.
  • OBJECTIVE: To present our clinical experience of 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen administered as an adjuvant chemotherapy to 2 patients with advanced jejunal adenocarcinoma.
  • A small bowel series as well as the abdominal computed tomography scan revealed an irregular narrowing lesion at the proximal jejunum.
  • The patient then underwent an exploratory laparotomy and the jejunal adenocarcinoma with localized peritoneal metastasis was found (R0 resection, T3N1M1, stage IV).
  • Chemotherapy with FOLFOX4 regimen of 12 cycles was initiated after the curative resection.
  • No adverse event was observed during the period of chemotherapy.
  • She also received the FOLFOX4 chemotherapy of 12 cycles with an uneventful course.
  • No obvious toxicity developed except for temporary grade I peripheral neuropathy and skin eruption.
  • CONCLUSION: This report showed that adjuvant chemotherapy with FOLFOX4 regimen seems effective and well tolerated in these 2 patients with advanced jejunal adenocarcinoma.
  • Further investigation of a large number of patients with long-term follow-up is needed to confirm these findings.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Jejunal Neoplasms / drug therapy
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Female. Fluorouracil / therapeutic use. Humans. Leucovorin / therapeutic use. Middle Aged. Organoplatinum Compounds / therapeutic use. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • (PMID = 18836281.001).
  • [ISSN] 1423-0151
  • [Journal-full-title] Medical principles and practice : international journal of the Kuwait University, Health Science Centre
  • [ISO-abbreviation] Med Princ Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


2. Otera H, Ikeda F, Nakagawa S, Kono Y, Sakurai T, Tada K, Hashimoto K, Ikeda A: Intussusception of small intestine due to metastasis of large cell carcinoma of the lung with a rhabdoid phenotype. Eur Respir Rev; 2010 Sep;19(117):248-52
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intussusception of small intestine due to metastasis of large cell carcinoma of the lung with a rhabdoid phenotype.
  • Large cell carcinoma of the lung with a rhabdoid phenotype is a rare type of lung cancer, and does not commonly metastasize to the small intestine.
  • Herein we describe a 63-yr-old Japanese male with ileus resulting from small intestinal metastasis from lung cancer.
  • Tumour enlargement was rapid and could not be treated with chemotherapy.
  • [MeSH-major] Carcinoma, Large Cell / complications. Carcinoma, Large Cell / secondary. Intussusception / etiology. Intussusception / pathology. Lung Neoplasms / complications. Lung Neoplasms / pathology
  • [MeSH-minor] Fatal Outcome. Humans. Intestine, Small / pathology. Intestine, Small / surgery. Male. Middle Aged. Phenotype. Rhabdoid Tumor / complications. Rhabdoid Tumor / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20956201.001).
  • [ISSN] 1600-0617
  • [Journal-full-title] European respiratory review : an official journal of the European Respiratory Society
  • [ISO-abbreviation] Eur Respir Rev
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


3. Okuno K: Surgical treatment for digestive cancer. Current issues - colon cancer. Dig Surg; 2007;24(2):108-14

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment for digestive cancer. Current issues - colon cancer.
  • BACKGROUND: Due to the westernization of the diet in Japan, the incidence of colorectal cancer has increased 4.5 times in the last 25 years.
  • In this review, the recent results of surgical treatment for colonic cancer and the future perspectives in Japan are described.
  • MATERIALS AND METHODS: A multi-institutional registry of large bowel cancer in Japan of 10,809 patients with colonic cancer treated from 1991 to 1994 was investigated.
  • The data have been published in the Guidelines of the Japanese Society for Cancer of the Colon and Rectum (2005).
  • Regarding laparoscopic surgery, 1,495 patients with colon cancer were examined in a multicenter study between April 1993 and August 2002.
  • This treatment protocol has now been accepted as a 'standard' operation by Japanese colorectal surgeons.
  • For patients undergoing a curative resection for colon cancer, the 5-year survival rates vary between 62 (stage III) and 91% (stage I).
  • Adjuvant chemotherapy using 5-FU/leucovorin or oral compounds is commonly administered to patients with stage III disease.
  • Laparoscopic surgery for colonic cancer yielded a comparable oncological outcome to that reported for conventional open surgery in the Japanese registry for all disease stages.
  • CONCLUSION: Radical resection with a D3 lymphadenectomy provided satisfactory 5-year survival for patients with stage I-III colon cancer in Japan.
  • Any further improvements depend on both identifying such patients at an earlier stage as well as developing new and effective treatment modalities.
  • [MeSH-minor] Humans. Lymph Node Excision. Neoplasm Metastasis. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 S. Karger AG, Basel.
  • (PMID = 17446704.001).
  • [ISSN] 0253-4886
  • [Journal-full-title] Digestive surgery
  • [ISO-abbreviation] Dig Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 21
  •  go-up   go-down


Advertisement
4. Bland AE, Everett EN, Pastore LM, Andersen WA, Taylor PT Jr: Predictors of suboptimal surgical cytoreduction in women with advanced epithelial ovarian cancer treated with initial chemotherapy. Int J Gynecol Cancer; 2008 Jul-Aug;18(4):629-36
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of suboptimal surgical cytoreduction in women with advanced epithelial ovarian cancer treated with initial chemotherapy.
  • The objective of this study was to retrospectively evaluate predictors of suboptimal surgical cytoreduction (SSC) in women with advanced epithelial ovarian cancer (EOC) treated with initial chemotherapy (IC).
  • All women with EOC treated with IC at our hospital between January 1, 1995, and January 1, 2003, were eligible; 128 patients met inclusion criteria and underwent retrospective chart review.
  • Eighty-four patients (66%) had an optimal surgical cytoreduction (OSC), 14 patients (11%) had an SSC, and 30 (23%) patients were treated with chemotherapy only (CO).
  • Patients in the SSC group had more small-bowel mesentery disease on preoperative computed tomography (CT) scan compared to the OSC group (38% SSC vs 6% OSC, P = 0.024).
  • Patients in the SSC group were also more likely to have disease on the liver surface, small-bowel surface, large-bowel mesentery, bladder peritoneum, spleen, and diaphragm that was not reported on preoperative CT but found at surgery.
  • For those patients highly likely to have an SSC, CO may be offered as a reasonable alternative, decreasing the morbidity of an extensive surgical procedure that may not provide survival benefit.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoplasms, Glandular and Epithelial / diagnosis. Neoplasms, Glandular and Epithelial / drug therapy. Neoplasms, Glandular and Epithelial / surgery. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery
  • [MeSH-minor] Algorithms. CA-125 Antigen / analysis. CA-125 Antigen / blood. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Neoplasm, Residual. Prognosis. Retrospective Studies. Risk Factors


5. Sawada T, Nishimura M, Hirose K: [Long-term survival in a case of large bowel cancer--efficacy of CPT-11-based chemotherapy]. Gan To Kagaku Ryoho; 2005 Jul;32(7):1059-61
Hazardous Substances Data Bank. FLOXURIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term survival in a case of large bowel cancer--efficacy of CPT-11-based chemotherapy].
  • A 77-year-old woman underwent an ileocecal resection and a partial resection of the small intestine for cecal cancer.
  • However, ileus caused by a recurrence in the small intestine was detected two years and four months postoperatively, so an ileal resection was performed.
  • Furthermore, metastases to the lungs, lymph nodes, and peritoneum were detected, and CPT-11-based chemotherapy was administered.
  • The patient was initially treated by combination therapy with a small dose of CPT-11 and CDDP.
  • The combination drugs were changed to MMC, 5'-DFUR, etc. while the appearance of adverse reactions was monitored.
  • Three years of continuous treatment served to prevent the proliferation of tumors.
  • At present, TS-1 chemotherapy is ongoing.
  • The results suggest that CPT-11-based chemotherapy can be continued by changing the combination of concomitant drugs while monitoring adverse reactions.
  • It thus may be an effective regimen for advanced and recurrent large bowel cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Colorectal Neoplasms / drug therapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Drug Administration Schedule. Female. Floxuridine / administration & dosage. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis. Mitomycin / administration & dosage. Peritoneal Neoplasms / secondary. Survivors

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16044974.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 039LU44I5M / Floxuridine; 50SG953SK6 / Mitomycin; 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; V1JK16Y2JP / doxifluridine; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


6. Brenner B, Shah MA, Gonen M, Klimstra DS, Shia J, Kelsen DP: Small-cell carcinoma of the gastrointestinal tract: a retrospective study of 64 cases. Br J Cancer; 2004 May 4;90(9):1720-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To better define its clinicopathological features, the records of all patients with this disease seen at Memorial Sloan Kettering Cancer Center between 1980 and 2002 (n=64) were reviewed.
  • The most common primary tumour locations were in the large bowel and oesophagus.
  • Predisposing medical conditions for non-small-cell cancers, positive family cancer history, and metachronous tumours were common.
  • In all, 37% had mixed tumour histology and 48% presented with extensive disease, according to the Veterans' Administration Lung Study group (VALSG) staging system used for small-cell lung cancer.
  • Treatment outcome in limited disease (LD) suggested a role for surgery and chemotherapy.
  • Mixed tumour histology is common and may affect therapy.
  • Surgery, combined with chemotherapy, should be considered for LD.
  • The value of the VALSG system was implied and possible differences from small-cell lung cancer were noted.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Jan 15;88(2):262-7 [10640955.001]
  • [Cites] Am J Clin Oncol. 1998 Oct;21(5):458-61 [9781599.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):523-33 [10931451.001]
  • [Cites] Am J Clin Oncol. 2000 Oct;23(5):455-9 [11039503.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):595-601 [11342770.001]
  • [Cites] Gan To Kagaku Ryoho. 2001 Sep;28(9):1283-6 [11579641.001]
  • [Cites] Ann Oncol. 2001 Sep;12(9):1321-5 [11697847.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):85-91 [11784874.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1184-97 [12218575.001]
  • [Cites] Clin Colorectal Cancer. 2001 Aug;1(2):87-94 [12445366.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2730-9 [15226341.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Cancer Chemother Rep 3. 1973 Mar;4(2):31-42 [4580860.001]
  • [Cites] Am J Gastroenterol. 1974 Jun;61(6):481-3 [4366115.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):515-9 [10027322.001]
  • [Cites] Hum Pathol. 1999 Feb;30(2):216-21 [10029452.001]
  • [Cites] J Pathol Bacteriol. 1952 Oct;64(4):889-91 [13000600.001]
  • [Cites] Hum Pathol. 1977 Jul;8(4):433-40 [892795.001]
  • [Cites] Cancer. 1980 Apr 1;45(7):1558-61 [7189441.001]
  • [Cites] Am J Epidemiol. 1980 Apr;111(4):444-52 [7377187.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 Jan;10(1):147-52 [6321409.001]
  • [Cites] Hum Pathol. 1984 May;15(5):460-8 [6327495.001]
  • [Cites] Cancer. 1984 Oct 15;54(8):1645-61 [6089995.001]
  • [Cites] Hum Pathol. 1987 Jan;18(1):9-21 [2434408.001]
  • [Cites] Am J Gastroenterol. 1987 Apr;82(4):382-5 [3031980.001]
  • [Cites] Medicine (Baltimore). 1987 Nov;66(6):457-71 [2824968.001]
  • [Cites] Cancer. 1989 Oct 1;64(7):1531-3 [2550125.001]
  • [Cites] Cancer. 1990 Feb 1;65(3):422-4 [1688727.001]
  • [Cites] Am J Clin Pathol. 1991 Mar;95(3):315-21 [1847579.001]
  • [Cites] Am J Gastroenterol. 1991 Sep;86(9):1167-75 [1715667.001]
  • [Cites] Eur J Cancer. 1992;29A(1):81-6 [1332739.001]
  • [Cites] Pathology. 1993 Jul;25(3):240-2 [8265240.001]
  • [Cites] Chest. 1995 Jan;107(1):179-81 [7813272.001]
  • [Cites] J Thorac Cardiovasc Surg. 1995 Feb;109(2):284-8 [7531797.001]
  • [Cites] South Med J. 1996 Sep;89(9):921-4 [8790320.001]
  • [Cites] Rev Esp Enferm Dig. 1996 Aug;88(8):533-8 [8962757.001]
  • [Cites] J Surg Oncol. 1997 Feb;64(2):130-4 [9047250.001]
  • [Cites] Acta Oncol. 1997;36(1):78-80 [9090972.001]
  • [Cites] Cancer. 1997 Oct 15;80(8):1366-72 [9338459.001]
  • [Cites] Oncology (Williston Park). 1998 Aug;12(8 Suppl 6):110-3 [9726102.001]
  • [Cites] Arch Pathol Lab Med. 2000 Feb;124(2):228-33 [10656731.001]
  • (PMID = 15150595.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2409752
  •  go-up   go-down


7. Park JS, Kim L, Kim CH, Bang BW, Lee DH, Jeong S, Shin YW, Kim HG: Synchronous large-cell neuroendocrine carcinoma and adenocarcinoma of the colon. Gut Liver; 2010 Mar;4(1):122-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous large-cell neuroendocrine carcinoma and adenocarcinoma of the colon.
  • Large-cell neuroendocrine carcinoma of the colon is a rare entity with a prognosis that is usually poor due to the high likelihood of early metastasis.
  • A 61-year-old man had surgery for colon cancer of the transverse colon and cecum.
  • Microscopic examination of the tumor showed that the location was the proximal transverse colon, with small nests containing rosettes and palisading patterns of large tumor cells with faintly granular cytoplasm.
  • The tumors were diagnosed as a large-cell neuroendocrine carcinoma of the colon.
  • In addition, the tumor of the cecum showed microscopic findings consistent with a well-differentiated adenocarcinoma.
  • The immunohistochemical panel showed that the tumor was negative for neuroendocrine markers.
  • Cancer metastasis was found in the peritoneum section of the small bowel.
  • Postoperative chemotherapy was applied.
  • The patient was alive with good performance after, and there was no sign of tumor progression.
  • This is the first case of a synchronous large-cell neuroendocrine carcinoma and adenocarcinoma of the colon.
  • The patient was treated successfully with debulking surgery and systemic chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rev Esp Enferm Dig. 2008 Jan;100(1):11-6 [18358055.001]
  • [Cites] Int J Colorectal Dis. 2008 Mar;23(3):325-7 [18064472.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Aug;19(4):553-76 [16183527.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Aug;19(4):491-505 [16183523.001]
  • [Cites] Pathol Int. 2005 Aug;55(8):524-9 [15998383.001]
  • [Cites] Gynecol Oncol. 2001 Jul;82(1):187-91 [11426984.001]
  • [Cites] Surgery. 1994 Jun;115(6):762-6 [8197570.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:13-27 [15153416.001]
  • [Cites] Anticancer Res. 2004 Mar-Apr;24(2C):1049-51 [15154621.001]
  • [Cites] Virchows Arch. 2002 Sep;441(3):256-63 [12242522.001]
  • [Cites] Cancer Res. 1994 Jul 1;54(13):3500-5 [8012973.001]
  • (PMID = 20479925.001).
  • [ISSN] 2005-1212
  • [Journal-full-title] Gut and liver
  • [ISO-abbreviation] Gut Liver
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2871610
  • [Keywords] NOTNLM ; Chemotherapy / Colonic neoplasms / Multiple primary neoplasms / Neuroendocrine carcinoma
  •  go-up   go-down


8. Chintamani, Singhal V, Bansal A, Bhatnagar D, Saxena S: Isolated colostomy site recurrence in rectal cancer-two cases with review of literature. World J Surg Oncol; 2007;5:52
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated colostomy site recurrence in rectal cancer-two cases with review of literature.
  • Various etiological factors like adenoma-cancer sequence, bile acids, recurrent and persistent physical damage at the colostomy site by faecal matter due to associated stomal stenosis have been considered responsible.
  • Two such cases are being reported and in both cases there was no evidence of any local recurrence in the pelvis or liver and distant metastasis.
  • Both patients had received adjuvant chemotherapy following surgery.
  • CASE PRESENTATION: First case was a 30-year-old male that had reported with large bowel obstruction due to an obstructing ulcero-proliferative growth (poorly differentiated adenocarcinoma) at the colostomy site after abdomino-perineal resection, performed for low rectal cancer six years previously.
  • Four years later he presented with massive malignant ascites, cachexia and multiple liver metastasis and succumbed to his disease.
  • Second case was a 47-year-old male that presented with acute large bowel obstruction due to an annular growth (well differentiated adenocarcinoma) in the upper rectum.
  • Five years following closure of colostomy, he presented with two parietal masses at the previous colostomy site scar, which, on fine needle aspiration cytology were found to be well-differentiated adenocarcinomas of colorectal type.
  • Surgery with microscopically free margins is recommended in the absence of metastatic disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastroenterol. 2002;37(5):387-90 [12051539.001]
  • [Cites] J Postgrad Med. 2003 Apr-Jun;49(2):157-8 [12867694.001]
  • [Cites] Gastroenterology. 1958 Jan;34(1):85-98 [13501357.001]
  • [Cites] Cancer. 1974 Jun;33(6):1630-4 [4834157.001]
  • [Cites] Dis Colon Rectum. 1983 Jan;26(1):50-2 [6822162.001]
  • [Cites] Dis Colon Rectum. 1966 Nov-Dec;9(6):441-6 [5926156.001]
  • (PMID = 17567928.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 10
  • [Other-IDs] NLM/ PMC1876234
  • [General-notes] NLM/ Original DateCompleted: 20070730
  •  go-up   go-down


9. Taghian A, Jeong JH, Mamounas E, Anderson S, Bryant J, Deutsch M, Wolmark N: Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. J Clin Oncol; 2004 Nov 1;22(21):4247-54
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials.
  • PURPOSE: To assess patterns of locoregional failure (LRF) in lymph node-positive (LN+) breast cancer patients treated with mastectomy and adjuvant chemotherapy (+/- tamoxifen) and without postmastectomy radiotherapy (PMRT) in five National Surgical Adjuvant Breast and Bowel Project trials.
  • Median follow-up time was 11.1 years.
  • Distribution of pathologic tumor size was < or = 2 cm, 2.1 to 5 cm, and more than 5 cm in 30%, 52%, and 11% of patients, respectively.
  • Ninety percent of patients received doxorubicin-based chemotherapy.
  • For patients with a tumor size of < or = 2 cm, 2.1 to 5.0 cm, and more than 5.0 cm, these incidences were 14.9%, 21.3%, and 24.6%, respectively (P < .0001).
  • Multivariate analysis showed age, tumor size, premenopausal status, number of LN+, and number of dissected LN as significant predictors for LRF as first event.
  • CONCLUSION: In patients with large tumors and four or more LN+, LRF as first event remains a significant problem.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / surgery. Mastectomy. Tamoxifen / therapeutic use
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Lymphatic Metastasis. Melphalan / administration & dosage. Methotrexate / administration & dosage. Middle Aged. Neoplasm Recurrence, Local. Proportional Hazards Models. Statistics, Nonparametric. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2004 Nov 1;22(21):4237-9 [15452185.001]
  • (PMID = 15452182.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10CA-12027; United States / NCI NIH HHS / CA / U10CA-69651-10; United States / NCI NIH HHS / CA / U10CA-69974
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q41OR9510P / Melphalan; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


10. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE Jr, Wickerham DL, Wolmark N: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol; 2006 Aug 10;24(23):3726-34
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
  • PURPOSE: The 21-gene recurrence score (RS) assay quantifies the likelihood of distant recurrence in women with estrogen receptor-positive, lymph node-negative breast cancer treated with adjuvant tamoxifen.
  • The relationship between the RS and chemotherapy benefit is not known.
  • METHODS: The RS was measured in tumors from the tamoxifen-treated and tamoxifen plus chemotherapy-treated patients in the National Surgical Adjuvant Breast and Bowel Project (NSABP) B20 trial.
  • Cox proportional hazards models were utilized to test for interaction between chemotherapy treatment and the RS.
  • RESULTS: A total of 651 patients were assessable (227 randomly assigned to tamoxifen and 424 randomly assigned to tamoxifen plus chemotherapy).
  • The test for interaction between chemotherapy treatment and RS was statistically significant (P = .038).
  • Patients with high-RS (> or = 31) tumors (ie, high risk of recurrence) had a large benefit from chemotherapy (relative risk, 0.26; 95% CI, 0.13 to 0.53; absolute decrease in 10-year distant recurrence rate: mean, 27.6%; SE, 8.0%).
  • Patients with low-RS (< 18) tumors derived minimal, if any, benefit from chemotherapy treatment (relative risk, 1.31; 95% CI, 0.46 to 3.78; absolute decrease in distant recurrence rate at 10 years: mean, -1.1%; SE, 2.2%).
  • Patients with intermediate-RS tumors did not appear to have a large benefit, but the uncertainty in the estimate can not exclude a clinically important benefit.
  • CONCLUSION: The RS assay not only quantifies the likelihood of breast cancer recurrence in women with node-negative, estrogen receptor-positive breast cancer, but also predicts the magnitude of chemotherapy benefit.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Gene Expression Regulation, Neoplastic. Neoplasm Proteins / metabolism. Receptors, Estrogen / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Linear Models. Lymphatic Metastasis. Methotrexate / administration & dosage. Middle Aged. Mitomycins / administration & dosage. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / prevention & control. Odds Ratio. Predictive Value of Tests. Prognosis. Proportional Hazards Models. Randomized Controlled Trials as Topic. Reverse Transcriptase Polymerase Chain Reaction. Risk Assessment. Risk Factors. Secondary Prevention. Tamoxifen / administration & dosage

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2006 Aug 10;24(23):3717-8 [16720679.001]
  • (PMID = 16720680.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10-CA-12027; United States / NCI NIH HHS / CA / U10-CA-37377; United States / NCI NIH HHS / CA / U10-CA-69651; United States / NCI NIH HHS / CA / U10-CA-69974
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mitomycins; 0 / Neoplasm Proteins; 0 / Receptors, Estrogen; 094ZI81Y45 / Tamoxifen; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate; CMF protocol; FuMi protocol
  •  go-up   go-down


11. Tsushima M, Matsuo K, Mizuta M, Ueda Y, Fujiwara K, Yonei T, Yamadori I, Sato T: [Pleomorphic carcinoma of the lung with uncommon initial manifestation of intestinal perforation]. Nihon Kokyuki Gakkai Zasshi; 2009 Jun;47(6):507-11
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 47-year-old woman suddenly developed abdominal pain and visited the emergency room of our hospital.
  • Chest and abdominal CT scan revealed free air in the abdominal cavity and a bulky pulmonary tumor in the right middle lobe.
  • Histological examination of the resected tissue revealed undifferentiated carcinoma, but the histological differentiation could not be determined.
  • We used immunohistochemical staining to distinguish primary non-small cell lung cancer from colon cancer; the resected tumor was positive for TTF-1 and CK7, but negative for CK20.
  • Therefore, by using immunohistochemical staining we could diagnose the tumor of the large intestine as metastasis from non-small cell lung cancer.
  • After the operation, systemic chemotherapy with carboplatin and docetaxel was repeated, but the lung tumor did not regress and the patient died.
  • Autopsy examination confirmed the histology of the lung tumor as pleomorphic carcinoma.
  • Morphological characteristics and the immunohistochemical staining pattern of the pulmonary tumor were consistent with that of the colon tumor.
  • In Japan, this is the first report in which the initial manifestation of lung cancer was perforation of the large intestine due to metastasis.
  • [MeSH-major] Carcinoma / pathology. Intestinal Perforation / etiology. Lung Neoplasms / pathology. Sigmoid Diseases / etiology. Sigmoid Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19601528.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


12. El Ajmi M, Ksantini R, Chebbi F, Makni A, Rebai W, Daghfous A, Bedioui H, Fteriche F, Jouini M, Kacem M, Ben Safta Z: Abdominal metastasis of a parosteal osteosarcoma of the femur: an unusual cause of large-bowel obstruction. Acta Chir Belg; 2009 Oct;109(5):633-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abdominal metastasis of a parosteal osteosarcoma of the femur: an unusual cause of large-bowel obstruction.
  • AIM: We report an unusual case of abdominal mass recurrence of parosteal osteosarcoma of the left distal femur treated eight years previously with wide resection, hip disarticulation and chemotherapy, which presented as an acute abdomen: we discuss the clinical outcomes of this rare entity.
  • CASE PRESENTATION: We present a 54-year-old patient with low-grade parosteal osteosarcoma of the left distal femur.
  • Left total hip disarticulation was indicated after several local relapses of the tumour following extensive resection and chemotherapy.
  • Eight years later, he presented with an acute large bowel obstruction secondary to a compression of the large bowel by an abdominal mass.
  • Abdominal computed tomography showed a large abdominal calcified mass with dilated large bowel loops.
  • The patient received adjuvant chemotherapy, but the response was poor: six months later, the patient presented with a peristomal mass and two pulmonary metastases.
  • CONCLUSION: Abdominal recurrence of parosteal osteosarcoma of the distal femur eight years after definitive surgery is rare.
  • [MeSH-major] Colonic Neoplasms / secondary. Femoral Neoplasms / pathology. Intestinal Obstruction / etiology. Osteosarcoma / secondary
  • [MeSH-minor] Colostomy. Female. Humans. Lung Neoplasms / secondary. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19994810.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


13. Mehrkhani F, Nasiri S, Donboli K, Meysamie A, Hedayat A: Prognostic factors in survival of colorectal cancer patients after surgery. Colorectal Dis; 2009 Feb;11(2):157-61
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in survival of colorectal cancer patients after surgery.
  • OBJECTIVE: To determine the factors affecting survival, following resection of large bowel for colorectal carcinoma.
  • METHOD: From the cancer database of a single referral institution, a total of 1090 patients who had undergone colorectal resection between 1999 and 2002 were identified.
  • Cases with recurrent colorectal cancer or previous history of neoadjuvant chemotherapy were excluded.
  • Criteria studied consisted of age, sex, TNM stage, T-status, nodal status, distant metastasis, histological grade, lymphatic and vascular invasion, tumour location, preoperative carcinoembryonic antigen (CEA) level and liver function tests.
  • RESULTS: The mean survival time for all patients was 42.8 (SEM = 2.8) months.
  • In univariate analysis, patients' age (P < 0.0001), TNM stage (P < 0.0001), T-status (P = 0.015), nodal status (P = 0.016), distant metastasis (P < 0.0001), grade (P = 0.005), lymphatic and vascular invasion (P < 0.0001) and presurgery CEA level > 5 ng/ml (P = 0.021) were found to be predictors that could affect survival.
  • CONCLUSION: Age, TNM stage, T-status, nodal status, distant metastasis, grade, lymphatic and vascular invasion and presurgery CEA level can predict the postsurgical survival rate in patients with colorectal cancer.
  • [MeSH-minor] Age Factors. Aged. Carcinoembryonic Antigen / blood. Cohort Studies. Female. Humans. Kaplan-Meier Estimate. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Colorectal Dis. 2009 Jun;11(5):538-9 [19508520.001]
  • (PMID = 18462239.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


14. Longo R, Morabito A, Carillio G, Lanzi G, Castellana MA, Amici S, Fanelli M, Gattuso D, Gasparini G: Multiorganic dissemination of a colorectal signet ring cell carcinoma with fulminant clinical course. Int J Gastrointest Cancer; 2006;37(1):49-54
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mucinous colorectal cancer with signet ring cell aspects is a rare form of adenocarcinoma representing about 2-5% of large bowel neoplasms.
  • The tumor frequently presents with late-stage or peritoneal spreading.
  • Local recurrence and distant metastases are common in spite of surgical operation and adjuvant treatment, conditioning a poor prognosis.
  • At the present, early diagnosis and complete resection are the most important approaches to improve the outcome.
  • In our report we describe a case of a 41-yr-old patient with very aggressive untreated metastatic colorectal signet ring cell carcinoma.
  • The fulminant tumor progression was really unexpected and misled every possible medical interpretation, leading to rapid worsening of the patient's clinical conditions and no chance for chemotherapy treatment.
  • The tumor mimicked the picture observed in the acute leukemia, developing diffuse infiltration in all serosal membranes, liver, lung, kidneys, multiple lymph nodes, and meninges, as revealed by the post-mortem medical report.
  • [MeSH-major] Carcinoma, Signet Ring Cell / pathology. Colorectal Neoplasms / pathology. Neoplasm Metastasis / pathology

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 1991 Sep-Oct;76(5):368-74 [1806439.001]
  • [Cites] Am J Gastroenterol. 1996 Oct;91(10):2195-9 [8855747.001]
  • [Cites] Ann Surg Oncol. 1996 Jul;3(4):344-8 [8790846.001]
  • [Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):77-99 [15000151.001]
  • [Cites] Mod Pathol. 2005 Feb;18(2):244-9 [15492759.001]
  • [Cites] Oncology. 1994 Jan-Feb;51(1):30-4 [8265100.001]
  • [Cites] Arch Pathol Lab Med. 1991 Oct;115(10):1022-5 [1654871.001]
  • [Cites] Dis Colon Rectum. 1999 Sep;42(9):1176-80 [10496558.001]
  • [Cites] N Engl J Med. 2000 Jan 13;342(2):69-77 [10631274.001]
  • [Cites] Tumori. 1996 Jul-Aug;82(4):408-12 [8890982.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Sep;8(3):183-8 [10981869.001]
  • [Cites] Cancer. 1983 Oct 15;52(8):1453-7 [6311394.001]
  • [Cites] Dis Colon Rectum. 1995 Nov;38(11):1189-92 [7587762.001]
  • [Cites] Am J Med. 1976 Feb;60(2):273-8 [1062163.001]
  • (PMID = 17290081.001).
  • [ISSN] 1537-3649
  • [Journal-full-title] International journal of gastrointestinal cancer
  • [ISO-abbreviation] Int J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Saigí E, Musulén E, García-García Y, Bombardó J, Nogué M, Seguí MA, Fernández-Morales L, Martinez-Peralta S, Rey M, Pericay C: Study of survival in non metastatic surgical colon cancer. J Clin Oncol; 2004 Jul 15;22(14_suppl):3750

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study of survival in non metastatic surgical colon cancer.
  • : 3750 Background: Colon cancer is the second neoplasm in men and women.
  • Its prognostic depends on TNM staging at diagnosis.
  • The treatment seems to improve the survival.
  • The aim of this study is to analyze our series of surgical colon cancer from 1996 to 2001.
  • METHODS: We analyzed 422 surgical colon cancer.
  • 70 patients were metastatic at the time of diagnosis or behind surgery (5 months).
  • The remainder 352 patients without metastases were analyzed.
  • The prognosis factors were: age at diagnosis, gender, locations in the large bowel, kind of surgery, pT, pN, stage, use of chemotherapy, disease free survival (DFS) and overall survival (OS).
  • RESULTS: The 352 non metastatic surgical colon cancer presented a mean age at diagnosis of 70,22 years (24 to 101).
  • The location in the bowel was: right 149 cases and left 203 cases. pT: pTis 6, pT114, pT2 43, pT3 244, pT4 41. pN: pN0 + pNX 229, pN1 70, pN2 52.
  • 145 patients received adjuvant chemotherapy.
  • CONCLUSIONS: The main prognostic factor for survival in colon cancer was the staging at diagnosis.
  • Patients with pT4 or pN2 should received aggressive treatments for the high risk of metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014094.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Bruce C, Köhne CH, Audisio RA: Treatment of advanced colorectal cancer in the elderly. Eur J Surg Oncol; 2007 Dec;33 Suppl 2:S84-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of advanced colorectal cancer in the elderly.
  • The recent improved survival in advanced colorectal cancer, owing in a large part to advances in adjuvant treatment, has mainly been reported in studies of younger patient groups.
  • Less is known about outcome in elderly patients, the fastest growing cohort of cancer patients.
  • The antimetabolite capecitabine used sequentially or concomitantly with the topoisomerase 1 inhibitor irinotecan or the DNA cross linking agent oxaliplatin are now considered to be the standard first line chemotherapy regime.
  • The role of surgery in advanced colorectal cancer in the elderly is restricted to the relief of bowel obstruction and where appropriate resection of hepatic metastasis.
  • Indeed, chronological age alone does not provide sufficient guidance when considering the appropriateness of any palliative treatment regime in the elderly.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Colorectal Neoplasms / therapy. Liver Neoplasms / therapy
  • [MeSH-minor] Age Factors. Aged. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Bevacizumab. Camptothecin / analogs & derivatives. Camptothecin / therapeutic use. Capecitabine. Cetuximab. Colectomy. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Fluorouracil / analogs & derivatives. Fluorouracil / therapeutic use. Hepatectomy. Humans. Organoplatinum Compounds / therapeutic use. Stents

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18006266.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 2S9ZZM9Q9V / Bevacizumab; 6804DJ8Z9U / Capecitabine; 7673326042 / irinotecan; PQX0D8J21J / Cetuximab; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  • [Number-of-references] 25
  •  go-up   go-down


17. Carballo N, González-Cortijo L, González-Martín A, Rojo A, Chiva L: Indications for adjuvant radiotherapy treatment after surgery and novel modalities for treatment. Gynecol Oncol; 2008 Sep;110(3 Suppl 2):S41-4
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indications for adjuvant radiotherapy treatment after surgery and novel modalities for treatment.
  • Carcinoma of the uterine cervix is a frequent common cancer in women.
  • Patients diagnosed with early stage cervix cancer are managed with surgery.
  • Only patients with poor prognostic factors as: large tumors (>or=4 cm), positive lymph nodes, positive and/or close margins <3 mm; can benefit from adjuvant radiotherapy.
  • Radiotherapy has been also recommended for a subgroup of patients with intermediate-risk factors as: large tumor diameter, deep stromal invasion and presence of tumor in capillary lymphatic space adjuvant.
  • In the presence of 2 of the 3 adverse risk factors, radiotherapy reduces tumor recurrence in stage IB cervical cancer with negative lymph nodes.
  • Radiotherapy plays an important role in the management of cervical cancer.
  • Conventional radiotherapy may treat a large amount of normal tissue resulting in acute toxicity.
  • The most frequent acute adverse events after external three-dimensional radiotherapy are bowel, bladder and hematological side effects.
  • With standard doses of external beam radiotherapy 45 Gy-50 Gy (1.8 Gy-2 Gy) grade 3-4 late toxicity occurs in about 10%-12%.
  • Intensity modulated radiation therapy (IMRT) represents an advance in treatment delivery with doses that conform tightly to the target, and may reduce the acute gastrointestinal and chronic toxicity when compared with conventional 3D radiotherapy.
  • Also IMRT treats less bone marrow and may lead to a better tolerance of chemotherapy.
  • [MeSH-minor] Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Neoplasm Staging. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18760712.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Ketata S, Boulaire JL, Soulimane B, Bargain A: Metachronous metastasis to the penis from a rectal adenocarcinoma. Clin Colorectal Cancer; 2007 Sep;6(9):657-9
Hazardous Substances Data Bank. CETUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metachronous metastasis to the penis from a rectal adenocarcinoma.
  • Penile metastases arise most frequently from genitourinary cancers, but can also arise from tumors of the large bowel; other primary sites are extremely uncommon.
  • We report the case of a 59-year-old patient with 2 penile metastases from a rectal adenocarcinoma, which was discovered 26 years after abdominoperineal resection.
  • Penile biopsy was carried out and established the metastatic nature.
  • The patient underwent palliative chemotherapy treatment with cetuximab/irinotecan.
  • All previously reported cases of penile metastasis from the rectum are reviewed.
  • Regardless of the treatment options, the prognosis of such metastasis remains poor.
  • [MeSH-major] Adenocarcinoma / secondary. Penile Neoplasms / secondary. Rectal Neoplasms / pathology
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Cetuximab. Humans. Immunohistochemistry. Male. Middle Aged. Palliative Care. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17945039.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 7673326042 / irinotecan; PQX0D8J21J / Cetuximab; XT3Z54Z28A / Camptothecin
  • [Number-of-references] 18
  •  go-up   go-down


19. Zhang S, Gao F, Luo J, Yang J: Prognostic factors in survival of colorectal cancer patients with synchronous liver metastasis. Colorectal Dis; 2010 Aug;12(8):754-61
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in survival of colorectal cancer patients with synchronous liver metastasis.
  • AIM: To determine the factors affecting the survival in colorectal cancer patients with synchronous liver metastases.
  • METHOD: A total of 168 patients who had been treated colorectal cancer with synchronous liver metastases at Guangxi Medical University from January 2000 to December 2005 were identified.
  • Criteria studied consisted of gender, age, time of symptoms, primary tumour location, primary tumour circumference, histological type, grade (tumour differentiation), T-status, N-status, large bowel obstruction, type of operation, primary tumour resection, ascities, location, number and diameter of liver lesions, preoperative CEA and chemotherapy.
  • RESULTS: The mean survival time for all patients was 18.71 (SEM = 1.59) months.
  • Univariate analysis share of grade (tumour differentiation), N-status, large bowel obstruction, operation, primary tumour resection, location, number and the most diameter of liver lesions, extrahepatic transfer, preoperative CEA level and chemotherapy to be predictors of survival.
  • In the Cox regression analysis, the N-status, large bowel obstruction, operation, diameter of liver lesion and extrahepatic transfer were independent factors related to survival.
  • CONCLUSION: Tumour differentiation, N-status, bowel obstruction, operation, primary tumour resection, location of liver metastasis, number of liver metastasis, diameter of liver metastasis, extrahepatic transfer, preoperative CEA level and chemotherapy are related to the survival of patients with colorectal cancer and synchronous liver metastases.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / pathology. Colorectal Neoplasms / mortality. Colorectal Neoplasms / pathology. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Carcinoembryonic Antigen / blood. Colon / pathology. Colon / surgery. Female. Humans. Intestinal Obstruction / mortality. Intestinal Obstruction / pathology. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Metastasis. Prognosis. Regression Analysis. Retrospective Studies. Risk Factors. Sex Characteristics. Time Factors. Tumor Burden. Young Adult

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19508508.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


20. Firat S, Murray K, Erickson B: High-dose whole abdominal and pelvic irradiation for treatment of ovarian carcinoma: long-term toxicity and outcomes. Int J Radiat Oncol Biol Phys; 2003 Sep 1;57(1):201-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose whole abdominal and pelvic irradiation for treatment of ovarian carcinoma: long-term toxicity and outcomes.
  • PURPOSE: To evaluate the role of high-dose whole abdominal and pelvic irradiation (WART) in the treatment of epithelial ovarian carcinoma.
  • None of the patients had received chemotherapy before RT.
  • Thirty-one patients received Alkeran or cyclophosphamide and two received cisplatin-based chemotherapy after WART.
  • The median whole abdominal dose was 36 Gy (range 9-45.5), delivered in a median of 30 fractions (range 8-46).
  • The median pelvic dose was 51 Gy (range 16-59).
  • The right lobe and a portion of the left lobe of the liver were shielded with custom blocks at a median dose of 25 Gy (range 9-41).
  • The median dose to the kidneys was 19 Gy (range 4-30).
  • For this group, a total abdominal dose of > or /=36 Gy was associated with a longer overall survival independent of stage, grade, and the amount of residual disease.
  • This was most likely due to a significant reduction in the incidence of abdominal recurrence in patients receiving >36 Gy to the whole abdomen (18% vs. 49%, p = 0.006).
  • Twenty-one percent (n = 15) of the patients developed Grade 3 or 4 (Radiation Therapy Oncology Group [RTOG] criteria) chronic small or large bowel toxicity.
  • Eleven percent of all patients had a small bowel obstruction requiring surgery.
  • A whole abdominal dose >30 Gy and a pelvic dose >50 Gy were associated with a significant increase in small bowel obstruction (p = 0.01) independent of other factors.
  • CONCLUSION: Survival after RT for ovarian carcinoma rivals that achieved with systemic chemotherapy.
  • The results of this study suggest a possible dose-control relationship between the whole abdominal dose and the risk of abdominal recurrence; however, a higher rate of small bowel obstruction was observed when greater abdominal doses and greater pelvic doses were combined.
  • Careful attention to balancing toxicity and efficacy is imperative if RT is to have a future role in the treatment of this disease.
  • [MeSH-major] Neoplasm Recurrence, Local / mortality. Ovarian Neoplasms / mortality. Ovarian Neoplasms / radiotherapy
  • [MeSH-minor] Abdomen / radiation effects. Adult. Aged. Dose-Response Relationship, Radiation. Female. Humans. Longitudinal Studies. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Pelvis / radiation effects. Prognosis. Radiation Injuries / etiology. Radiotherapy / adverse effects. Radiotherapy Dosage. Retrospective Studies. Risk Factors. Survival Analysis. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12909234.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


21. Nikolaeva TG, Dobrynin IaV, Akhundov AA, Prorokov VV, Davydov MI: [DNA flow cytometry in the prognostication of certain malignant neoformations]. Vopr Onkol; 2001;47(6):684-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [DNA flow cytometry in the prognostication of certain malignant neoformations].
  • The investigation included 314 patients: primary cancer of the lung (96), head and neck (146) and large bowel (72).
  • Patients received surgery alone or surgery plus either radiotherapy or chemotherapy; they were followed up for 6-20 months.
  • The recurrence rates in cases of aneuploid cancers were more than 3 times those of diploidy (21.0-43.2 and 4.5-14.5%, respectively).
  • Similarly, survival after surgery alone, preoperative chemotherapy and postoperative radiotherapy among diploid patients was longer than in aneuploid ones.
  • Hence, DNA ploidy examination of tumors is of great informative value in prognosing tumor process and working out individually-tailored approach to treatment.
  • [MeSH-major] Adenocarcinoma / genetics. Aneuploidy. Carcinoma, Squamous Cell / genetics. Colonic Neoplasms / genetics. DNA, Neoplasm. Diploidy. Flow Cytometry. Head and Neck Neoplasms / genetics. Lung Neoplasms / genetics
  • [MeSH-minor] Follow-Up Studies. Humans. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Prognosis. Sigmoid Neoplasms / genetics. Sigmoid Neoplasms / mortality. Time Factors

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11826489.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


22. Kaur N, Vijayaragavan P, Aggarwal S: Large nodal metastases from carcinoid tumor causing bowel obstruction. Indian J Gastroenterol; 2003 Mar-Apr;22(2):69-70
MedlinePlus Health Information. consumer health - Intestinal Obstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large nodal metastases from carcinoid tumor causing bowel obstruction.
  • Exploration showed extensive nodal metastases but no primary lesion was seen.
  • Histology revealed carcinoid tumor with small cell differentiation.
  • A trial of chemotherapy gave no response.
  • [MeSH-major] Carcinoid Tumor / complications. Intestinal Obstruction / etiology. Neoplasms, Unknown Primary
  • [MeSH-minor] Abdominal Neoplasms / complications. Adult. Humans. Lymphatic Metastasis. Male

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12696834.001).
  • [ISSN] 0254-8860
  • [Journal-full-title] Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology
  • [ISO-abbreviation] Indian J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


23. O'Connell MJ, Lavery I, Yothers G, Paik S, Clark-Langone KM, Lopatin M, Watson D, Baehner FL, Shak S, Baker J, Cowens JW, Wolmark N: Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol; 2010 Sep 01;28(25):3937-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin.
  • PURPOSE: These studies were conducted to determine the relationship between quantitative tumor gene expression and risk of cancer recurrence in patients with stage II or III colon cancer treated with surgery alone or surgery plus fluorouracil (FU) and leucovorin (LV) to develop multigene algorithms to quantify the risk of recurrence as well as the likelihood of differential treatment benefit of FU/LV adjuvant chemotherapy for individual patients.
  • PATIENTS AND METHODS: We performed quantitative reverse transcription polymerase chain reaction (RT-qPCR) on RNA extracted from fixed, paraffin-embedded (FPE) tumor blocks from patients with stage II or III colon cancer who were treated with surgery alone (n = 270 from National Surgical Adjuvant Breast and Bowel Project [NSABP] C-01/C-02 and n = 765 from Cleveland Clinic [CC]) or surgery plus FU/LV (n = 308 from NSABP C-04 and n = 508 from NSABP C-06).
  • Seven recurrence-risk genes, six FU/LV-benefit genes, and five reference genes were selected, and algorithms were developed to identify groups of patients with low, intermediate, and high likelihood of recurrence and benefit from FU/LV.
  • CONCLUSION: RT-qPCR of FPE colon cancer tissue applied to four large independent populations has been used to develop multigene algorithms for estimating recurrence risk and benefit from FU/LV.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / genetics. Gene Expression Profiling
  • [MeSH-minor] Algorithms. Chemotherapy, Adjuvant. Combined Modality Therapy. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Recurrence. Reverse Transcriptase Polymerase Chain Reaction

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2004 Jan;164(1):35-42 [14695316.001]
  • [Cites] N Engl J Med. 2003 Jul 17;349(3):247-57 [12867608.001]
  • [Cites] Oncogene. 2004 Feb 19;23(7):1377-91 [14973550.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1564-71 [15051756.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1572-82 [15117979.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2343-51 [15175436.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3408-19 [15199089.001]
  • [Cites] J Natl Cancer Inst. 1988 Mar 2;80(1):30-6 [3276901.001]
  • [Cites] J Clin Oncol. 1990 Sep;8(9):1466-75 [2202789.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1879-87 [8410113.001]
  • [Cites] N Engl J Med. 1994 Jul 28;331(4):213-21 [8015568.001]
  • [Cites] Ann Intern Med. 1995 Mar 1;122(5):321-6 [7847642.001]
  • [Cites] J Clin Oncol. 1995 Dec;13(12):2936-43 [8523058.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):246-50 [8996149.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):427-33 [9469325.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1349-55 [10334518.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1356-63 [10334519.001]
  • [Cites] Br J Cancer. 1958 Sep;12(3):309-20 [13596482.001]
  • [Cites] Gastroenterology. 2004 Dec;127(6):1678-84 [15578504.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2817-26 [15591335.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):609-18 [15659508.001]
  • [Cites] J Chemother. 2004 Nov;16 Suppl 4:25-30 [15688605.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3526-35 [15908663.001]
  • [Cites] Oncol Rep. 2005 Jul;14(1):241-9 [15944796.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5451-61 [16061861.001]
  • [Cites] Gastroenterology. 2005 Sep;129(3):874-84 [16143127.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9053-4 [16301590.001]
  • [Cites] Cancer Invest. 2006 Mar;24(2):215-7 [16537192.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2059-64 [16648506.001]
  • [Cites] Clin Adv Hematol Oncol. 2006 Mar;4(3):219-24 [16728933.001]
  • [Cites] J Clin Oncol. 2006 Aug 10;24(23):3726-34 [16720680.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4685-91 [16966692.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5313-27 [17060676.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2198-204 [17470851.001]
  • [Cites] Cancer Metastasis Rev. 2007 Jun;26(2):225-39 [17440684.001]
  • [Cites] BMC Genomics. 2007;8:279 [17697383.001]
  • [Cites] Lancet. 2007 Dec 15;370(9604):2020-9 [18083404.001]
  • [Cites] J Clin Oncol. 2009 Jul 1;27(19):3109-16 [19451431.001]
  • [Cites] Gastroenterology. 2004 Feb;126(2):394-401 [14762775.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3553-9 [10550154.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):1063-72 [10741735.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1322-7 [10778957.001]
  • [Cites] Gastroenterology. 2001 Jul;121(1):198-213 [11438509.001]
  • [Cites] Lancet. 2002 Nov 2;360(9343):1381-91 [12423985.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):241-50 [12525515.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):786-91 [12576451.001]
  • [Cites] Br J Cancer. 2003 Mar 24;88(6):957-64 [12644837.001]
  • [CommentIn] J Clin Oncol. 2010 Sep 1;28(25):3904-7 [20679612.001]
  • (PMID = 20679606.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10-CA-69651; United States / NCI NIH HHS / CA / U10-CA-37377; United States / NCI NIH HHS / CA / U10 CA012027; United States / NCI NIH HHS / CA / U10-CA-69974; United States / NCI NIH HHS / CA / U10-CA-12027; United States / NCI NIH HHS / CA / U10 CA069651; United States / NCI NIH HHS / CA / U10 CA069974; United States / NCI NIH HHS / CA / U10 CA037377
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2940392
  •  go-up   go-down


24. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST): Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol; 2010 Mar 01;28(7):1247-53
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients.
  • PURPOSE: The Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST) project aims to additionally explore the data of the two large, randomized, cooperative-group studies comparing two doses of imatinib (400 mg daily v twice daily) in 1,640 patients with advanced GIST.
  • Investigated cofactors included age, sex, performance status (PS), primary tumor site, time from diagnosis, prior therapies, baseline biology, and KIT/PDGFRalpha mutations for a subset of 772 patients.
  • The multivariate prognostic models included the following adverse factors: male sex, poor PS, and high baseline neutrophils counts (PFS and OS); low hemoglobin and GIST from small bowel origin (PFS); and advanced age, large tumor size, low albumin level, and prior chemotherapy (OS).
  • In patients analyzed for mutations, patients with wild type, patients with KIT exon 9 mutations, and patients with other mutations had worse prognoses than patients with KIT exon 11 mutations for both end points.
  • The mutation status was the only predictive factor for the PFS benefit attributed to high-dose treatment that resulted in significantly longer PFS (and higher objective response rate) for patients with KIT exon 9 mutations.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Gastrointestinal Stromal Tumors / drug therapy. Piperazines / administration & dosage. Protein Kinase Inhibitors / administration & dosage. Pyrimidines / administration & dosage
  • [MeSH-minor] Benzamides. Disease-Free Survival. Exons. Female. Humans. Imatinib Mesylate. Male. Mutation. Neoplasm Metastasis. Prognosis. Proto-Oncogene Proteins c-kit / genetics

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2001 Oct 27;358(9291):1421-3 [11705489.001]
  • [Cites] J Clin Oncol. 2008 Nov 20;26(33):5360-7 [18955451.001]
  • [Cites] Lancet Oncol. 2002 Nov;3(11):655-64 [12424067.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(14):2006-11 [12957454.001]
  • [Cites] J Clin Oncol. 2004 Sep 15;22(18):3813-25 [15365079.001]
  • [Cites] Lancet. 2004 Sep 25-Oct 1;364(9440):1127-34 [15451219.001]
  • [Cites] Stat Med. 1984 Apr-Jun;3(2):143-52 [6463451.001]
  • [Cites] Stat Med. 1992 Dec;11(16):2093-109 [1293671.001]
  • [Cites] Gastroenterology. 2005 Feb;128(2):270-9 [15685537.001]
  • [Cites] Cancer. 2005 Feb 15;103(4):821-9 [15648083.001]
  • [Cites] Eur J Cancer. 2005 Aug;41(12):1751-7 [16098458.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5795-804 [16110036.001]
  • [Cites] Eur J Cancer. 2006 May;42(8):1093-103 [16624552.001]
  • [Cites] Eur J Cancer. 2006 Sep;42(14):2277-85 [16876399.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4764-74 [16954519.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):626-32 [18235122.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • (PMID = 20124181.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA047577; United States / NCI NIH HHS / CA / N01 CA004919; United States / NCI NIH HHS / CA / U10 CA032291; United States / NCI NIH HHS / CA / U10 CA027525; United States / NCI NIH HHS / CA / U10 CA035091; United States / NCI NIH HHS / CA / U10 CA027057; United States / NCI NIH HHS / CA / N01 CA035176; United States / NCI NIH HHS / CA / U10 CA071323; United States / NCI NIH HHS / CA / U10 CA077658; United States / NCI NIH HHS / CA / U10 CA004919; United States / NCI NIH HHS / CA / U10 CA045560; United States / NCI NIH HHS / CA / U10 CA063845; United States / NCI NIH HHS / CA / U10 CA063850; United States / NCI NIH HHS / CA / N01 CA032102; United States / NCI NIH HHS / CA / N01 CA013612; United States / NCI NIH HHS / CA / U10 CA035192; United States / NCI NIH HHS / CA / U10 CA021115; United States / NCI NIH HHS / CA / U10 CA013612; United States / NCI NIH HHS / CA / U10 CA031946; United States / NCI NIH HHS / CA / U10 CA033601; United States / NCI NIH HHS / CA / N01 CA045807; United States / NCI NIH HHS / CA / U10 CA011488; United States / NCI NIH HHS / CA / U10 CA014028; United States / NCI NIH HHS / CA / N01 CA035119; United States / NCI NIH HHS / CA / N01 CA046441; United States / NCI NIH HHS / CA / U10 CA114558; United States / NCI NIH HHS / CA / U10 CA035281; United States / NCI NIH HHS / CA / U10 CA077440; United States / NCI NIH HHS / CA / N01 CA063844; United States / NCI NIH HHS / CA / U10 CA035261; United States / NCI NIH HHS / CA / U10 CA035178; United States / NCI NIH HHS / CA / R01 CA106588; United States / NCI NIH HHS / CA / U10 CA041287; United States / NCI NIH HHS / CA / U10 CA045450; United States / NCI NIH HHS / CA / U10 CA032102; United States / NCI NIH HHS / CA / U10 CA035113; United States / NCI NIH HHS / CA / U10 CA046282; United States / NCI NIH HHS / CA / U10 CA047559; United States / NCI NIH HHS / CA / U10 CA077651; United States / NCI NIH HHS / CA / U10 CA035262; United States / NCI NIH HHS / CA / N01 CA035178; United States / NCI NIH HHS / CA / N01 CA038926; United States / NCI NIH HHS / CA / N01 CA027057; United States / NCI NIH HHS / CA / U10 CA046441; United States / NCI NIH HHS / CA / U10 CA045377; United States / NCI NIH HHS / CA / U10 CA058882; United States / NCI NIH HHS / CA / U10 CA020319; United States / NCI NIH HHS / CA / U10 CA038926; United States / NCI NIH HHS / CA / U10 CA086780; United States / NCI NIH HHS / CA / U10 CA042777; United States / NCI NIH HHS / CA / U10 CA035119; United States / NCI NIH HHS / CA / U10 CA046368; United States / NCI NIH HHS / CA / U10 CA035176; United States / NCI NIH HHS / CA / U10 CA035090; United States / NCI NIH HHS / CA / U10 CA063844; United States / NCI NIH HHS / CA / U10 CA003927; United States / NCI NIH HHS / CA / U10 CA058861; United States / NCI NIH HHS / CA / U10 CA045807; United States / NCI NIH HHS / CA / N01 CA045560
  • [Publication-type] Comparative Study; Journal Article; Meta-Analysis
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Other-IDs] NLM/ PMC2834472
  •  go-up   go-down


25. Gattai R, Mascitelli EM, Bechi P, Pace M: [Integrated therapeutic strategy in large bowel neoplastic occlusion. An innovative therapeutic protocol]. Ann Ital Chir; 2007 Jul-Aug;78(4):295-301
MedlinePlus Health Information. consumer health - Intestinal Obstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Integrated therapeutic strategy in large bowel neoplastic occlusion. An innovative therapeutic protocol].
  • [Transliterated title] Strategia terapeutica integrata nelle neoplasie occludenti del grosso intestino. Un protocollo terapeutico innovativo.
  • BACKGROUND: Occlusive complication is a common event in the colo-rectal cancer (20-30% of cases).
  • Operative mortality and 5 yrs survival of not occlusive cancer vs occlusive cancer is 11% vs 23% and 45% vs 25% rispectively.
  • In occlusive cancer the level of parietal infiltration affects considerably the local and peritoneal recurrence.
  • 50% of all patients underwent a surgical re-operation for colo-rectal cancer have peritoneal neoplastic implant.
  • AIM: The resolution of occlusive complication in immediate or delayed urgency with decompressive derivation, it allows to perform an integrated treatment of choice that it could guarantee the oncological radical procedure.
  • RATIONALE-METHODS: The intraperitoneal hyperthermic chemotherapy (IPHC) combined with radical or cytoriductive surgery performs its action through sinergistic effects of high dosage and concentration of drugs and hyperthermia.
  • EXPECTED RESULTS: In radical surgery with curative intent, the association with IPHC ("preventive" adjuvant) has got as objective the distruction of microscopic local or peritoneal metastasis.
  • In occlusive cancer with synchronous or metachronous peritoneal carcinomatosis, the performance of the cytoreductive surgery with IPHC ("therapeutic" adjuvant) is the only treatment that improves the survival and the quality of remainig life.
  • These data lead us to believe that an optimal eradication of micro and/or macroscopic peritoneal spreading could be optained also in occlusive colo-rectal cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Chemotherapy, Cancer, Regional Perfusion / methods. Colorectal Neoplasms. Hyperthermia, Induced / methods. Intestinal Obstruction. Intestine, Large
  • [MeSH-minor] Combined Modality Therapy / methods. Humans

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17990604.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


26. Pawlik TM, Vauthey JN, Abdalla EK, Pollock RE, Ellis LM, Curley SA: Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver. Arch Surg; 2006 Jun;141(6):537-43; discussion 543-4
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver.
  • HYPOTHESIS: A subset of patients with sarcoma liver metastasis may benefit from hepatic resection and/or ablation.
  • DESIGN: Retrospective review of prospectively collected cancer center database records.
  • PATIENTS AND METHODS: Sixty-six patients who underwent hepatic resection and/or open radiofrequency ablation of metastatic sarcoma between July 1, 1996, and April 30, 2005, were identified from the database.
  • RESULTS: The primary sarcoma site was the abdomen or retroperitoneum (n = 22), stomach (n = 18), small or large bowel (n = 17), pelvis (n = 4), uterus (n = 3), or other (n = 2).
  • Tumor pathologic types included gastrointestinal stromal tumor (n = 36), leiomyosarcoma (n = 18), and sarcoma not otherwise classified (n = 12).
  • Treatment with radiofrequency ablation (either alone or combined with resection) (P = .002) and lack of adjuvant chemotherapy (P = .01) predicted shorter disease-free survival.
  • Patients with gastrointestinal stromal tumor who were treated with adjuvant imatinib mesylate had the longest median survival (not reached) (P = .003).
  • CONCLUSIONS: Long-term survival can be achieved following surgical treatment of sarcoma liver metastasis, especially in patients with gastrointestinal stromal tumor.
  • Patients with sarcoma liver metastasis should be evaluated by a multidisciplinary team, as recurrence is common and adjuvant therapy may prolong survival.
  • [MeSH-major] Catheter Ablation. Hepatectomy. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Sarcoma / secondary. Sarcoma / surgery
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Digestive System Neoplasms / pathology. Disease-Free Survival. Female. Gastrointestinal Stromal Tumors / pathology. Humans. Male. Middle Aged. Retroperitoneal Neoplasms / pathology. Retrospective Studies. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16785353.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


27. Mizushima T, Sando K, Ito T, Mikata S, Nonaka K, Ide H, Michiura T, Kainuma S, Yamanaka H, Iwase K: [A case of advanced colon cancer responding completely to systemic 5-fluorouracil/l-leucovorin therapy]. Gan To Kagaku Ryoho; 2004 Nov;31(12):2047-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced colon cancer responding completely to systemic 5-fluorouracil/l-leucovorin therapy].
  • A 79-year-old man was admitted for advanced transverse colon cancer with large bowel obstruction.
  • Twelve years earlier he underwent a total gastrectomy with Roux-en Y reconstruction for gastric cancer.
  • No metastasis was detected preoperatively.
  • Exploratory laparotomy revealed massive direct invasion of the mesenterium of the jejunum for Roux-en Y reconstruction.
  • Systemic chemotherapy with 5-fluorouracil and l-leucovorin was scheduled for a total of 4 courses postoperatively.
  • There was no severe side effect during chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Colostomy. Combined Modality Therapy. Drug Administration Schedule. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Male. Neoplasm Invasiveness

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15570938.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


28. Fung CL, Chan C, Jankova L, Dent OF, Robertson G, Molloy M, Bokey L, Chapuis PH, Lin BP, Clarke SJ: Clinicopathological correlates and prognostic significance of maspin expression in 450 patients after potentially curative resection of node-positive colonic cancer. Histopathology; 2010 Feb;56(3):319-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological correlates and prognostic significance of maspin expression in 450 patients after potentially curative resection of node-positive colonic cancer.
  • AIMS: The tumour suppressor maspin has been investigated for its association with conventional histopathological features in colorectal cancer and for its potential as an independent predictor of survival and response to adjuvant chemotherapy.
  • The aim of this study was to examine associations between maspin expression, other histopathology and survival in a large consecutive series of patients after potentially curative resection of node-positive colonic adenocarcinoma.
  • METHODS AND RESULTS: Nuclear and cytoplasmic maspin expression in both superficial and deep parts of the tumour were assessed retrospectively by tissue microarray and immunohistochemistry in specimens from 450 patients whose other histopathology had been recorded in a prospective hospital registry of large bowel cancer resections from 1971 to 2001 with a minimum follow-up of 5 years.
  • CONCLUSIONS: In this large and thoroughly documented series of patients with clinicopathological stage C colonic tumour, maspin expression was correlated with few other conventional histopathology variables and was not a significant prognostic factor.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / analysis. Colonic Neoplasms / metabolism. Serpins / biosynthesis
  • [MeSH-minor] Aged. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Lymphatic Metastasis / pathology. Male. Prognosis. Tissue Array Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20459532.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / SERPIN-B5; 0 / Serpins
  •  go-up   go-down


29. Cianfrocca M: Overcoming recurrence risk: extended adjuvant endocrine therapy. Clin Breast Cancer; 2008 Dec;8(6):493-500
Hazardous Substances Data Bank. LETROZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overcoming recurrence risk: extended adjuvant endocrine therapy.
  • Recurrence risk after initial treatment of breast cancer is a major concern for patients.
  • Although tamoxifen therapy has been shown to be effective in preventing recurrences and cancer-related deaths, recurrences continue to be an issue for patients after the 5-year therapy period.
  • Until recently, there were no therapeutic options available for risk reduction in the period after the first 5 years of tamoxifen (the extended adjuvant setting).
  • The introduction of the aromatase inhibitors (AIs), which have a different mechanism of action than tamoxifen, has provided an option for postmenopausal women seeking to extend their adjuvant hormonal treatment.
  • The Canadian-led MA.17 trial specifically addressed this issue, and the results showed a clear, significant benefit of letrozole, improving disease-free survival over placebo among postmenopausal women who already had 5 years of adjuvant tamoxifen treatment.
  • Recent analyses from MA.17 and other trials, such as the Austrian Breast and Colorectal Cancer Study Group 6a and National Surgical Adjuvant Breast and Bowel Project B-33, confirm the beneficial effect of extending adjuvant hormonal therapy with an AI and identify a large group of patients who could benefit from this therapeutic option.
  • Recent post-unblinding analyses from the MA.17 trial have also shown that there is a benefit for patients to initiate late extended adjuvant letrozole therapy, even after a prolonged period off tamoxifen.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Aromatase Inhibitors / therapeutic use. Breast Neoplasms / drug therapy. Nitriles / therapeutic use. Postmenopause. Tamoxifen / therapeutic use. Triazoles / therapeutic use
  • [MeSH-minor] Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Lymphatic Metastasis / prevention & control. Neoplasm Metastasis / prevention & control. Neoplasm Recurrence, Local / prevention & control

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19073503.001).
  • [ISSN] 1526-8209
  • [Journal-full-title] Clinical breast cancer
  • [ISO-abbreviation] Clin. Breast Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Aromatase Inhibitors; 0 / Nitriles; 0 / Triazoles; 094ZI81Y45 / Tamoxifen; 7LKK855W8I / letrozole
  • [Number-of-references] 40
  •  go-up   go-down


30. Onishi H, Yamaguchi M, Kuriyama K, Tsukamoto T, Ishigame K, Ichikawa T, Aoki S, Yoshikawa T, Araki T, Nambu A, Araki T, Hashi A, Yasumizu T, Hoshi K, Ito H: Effect of concurrent intra-arterial infusion of platinum drugs for patients with stage III or IV uterine cervical cancer treated with radical radiation therapy. Cancer J Sci Am; 2000 Jan-Feb;6(1):40-5
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of concurrent intra-arterial infusion of platinum drugs for patients with stage III or IV uterine cervical cancer treated with radical radiation therapy.
  • PURPOSE: The purpose of this study was to explore the effect of concurrent intra-arterial infusion of platinum drugs in patients with stage III or IV uterine cervical cancer treated with radical radiation therapy.
  • PATIENTS AND METHODS: Thirty-three patients with advanced (stage IIIA, 2; IIIB, 28; IVA, 3) uterine cervical squamous cell carcinoma were randomized into a concurrent intra-arterial infusion of platinum drugs with radiation therapy (IAPRT) group (18 patients) and a radiation therapy alone group (15 patients).
  • After altering intrapelvic blood flow by embolization of the superior and inferior gluteal arteries under pelvic angiography, intra-arterial infusion of platinum drug through catheters inserted into both internal iliac arteries was performed concurrently with radiation therapy.
  • One-shot infusion of cisplatin (100 mg/m2) twice with a 2- to 3-week interval was performed in eight patients, weekly infusion of carboplatin (100 mg/m2) via a reservoir five to six times was performed in four patients, and daily shot of cisplatin (10 mg/body) or 21 days via a reservoir was performed in six patients.
  • Radiation therapy consisted of external-beam irradiation of 50 Gy/25 fractions/5 weeks for the whole pelvis with midline block after 30 Gy and intracavitary high-dose-rate brachytherapy using tandem and ovoids of 24 Gy/4 fractions/4 weeks to point A.
  • RESULTS: The local complete response rate of the IAPRT group was 94% and was significantly higher than that of the radiation therapy group (67%).
  • There were no significant differences in local response in the three drug delivery methods.
  • Two- and 5-year overall survival rates were 54.5% and 44.4% in the IAPRT group, and 74.5% and 50.0% in the radiation therapy group, respectively.
  • In the IAPRT group, grade 3 or 4 acute bowel complications were seen in 33% of patients, grade 3 or 4 late bowel complications were seen 44%, and grade 3 or 4 myelosuppression was seen in 33%, and these complications were seen more in the IAPRT group than in the radiation therapy group and caused death in some patients.
  • CONCLUSIONS: IAPRT had a better local response than radiation therapy but showed no proof of control over recurrence and had a poorer survival than radiation therapy.
  • There were many local recurrences and distant metastases, contrary to the better first response of the IAPRT group over the radiation therapy group.
  • Complications of the IAPRT group were very severe and made the patient's performance status and prognosis worse than in the radiation therapy group.
  • Furthermore, we should re-examine the indication of IAPRT in patients with a large tumor because local recurrence and distant metastasis would be inevitable.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Embolization, Therapeutic. Female. Humans. Infusions, Intra-Arterial. Middle Aged. Neoplasm Staging. Survival Analysis

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10696738.001).
  • [ISSN] 1081-4442
  • [Journal-full-title] The cancer journal from Scientific American
  • [ISO-abbreviation] Cancer J Sci Am
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] UNITED STATES
  •  go-up   go-down


31. Stoehlmacher J, Lenz HJ: Cyclooxygenase-2 inhibitors in colorectal cancer. Semin Oncol; 2003 Jun;30(3 Suppl 6):10-6
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclooxygenase-2 inhibitors in colorectal cancer.
  • Large retrospective and prospective population-based studies have shown that the use of both nonselective, nonsteroidal anti-inflammatory drugs and selective COX-2 inhibitors are associated with decreased colorectal cancer incidence and mortality rate.
  • The inducible COX-2 isoform is overexpressed in colorectal tissues and is associated with critical events of tumorigenesis.
  • Inhibition of COX-2 favors apoptosis and causes a dose-dependent decline of tumor growth and metastasis in these models.
  • These data, together with the fact that COX-2 inhibitors cause less toxic side effects compared with nonselective nonsteroidal anti-inflammatory drugs, render these new compounds promising candidates in chemoprevention and treatment of colorectal cancer.
  • However, further clinical studies are needed to evaluate whether COX-2 inhibition will be effective in all types of colorectal tumor tissues.
  • This is especially true for neoplastic lesions that express COX-2 at a lower level (eg, hereditary nonpolyposis colorectal cancer) and for colorectal tumors of patients with inflammatory bowel disease.
  • In summary, COX-2 inhibitors represent a new and very promising group of chemotherapeutic agents with great potential for both colorectal cancer prevention and treatment.
  • [MeSH-major] Colorectal Neoplasms / drug therapy. Cyclooxygenase Inhibitors / therapeutic use. Isoenzymes / antagonists & inhibitors
  • [MeSH-minor] Animals. Apoptosis / drug effects. Clinical Trials as Topic. Cyclooxygenase 1. Cyclooxygenase 2. Cyclooxygenase 2 Inhibitors. Humans. Membrane Proteins. Neovascularization, Pathologic / enzymology. Prostaglandin-Endoperoxide Synthases / biosynthesis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Elsevier Inc. All rights reserved.
  • (PMID = 12802790.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K24 CA82754; United States / NCI NIH HHS / CA / P30 CA14089; United States / NCI NIH HHS / CA / R01 CA82655
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / Cyclooxygenase Inhibitors; 0 / Isoenzymes; 0 / Membrane Proteins; EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS1 protein, human; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  • [Number-of-references] 56
  •  go-up   go-down


32. Bryant J, Fisher B, Dignam J: Duration of adjuvant tamoxifen therapy. J Natl Cancer Inst Monogr; 2001;(30):56-61
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Duration of adjuvant tamoxifen therapy.
  • The benefit of using adjuvant tamoxifen to treat breast cancer has been firmly established for patients with estrogen receptor (ER)-positive tumors, regardless of age, lymph node status, or menopausal status.
  • Uncertainty remains, however, regarding the optimal duration of tamoxifen therapy.
  • We reviewed the findings of randomized clinical trials that directly compared alternative treatment durations.
  • Trials comparing short-term adjuvant treatment with tamoxifen (i.e., 1-3 years) with treatments having durations of about 5 years consistently have demonstrated additional benefits stemming from the longer therapy.
  • Trials testing 5 years of treatment with longer durations have, in the aggregate, suggested no additional benefit for the patient.
  • Nevertheless, the number of recurrences reported to date in these trials is not large, and the results of the individual trials are heterogeneous.
  • Furthermore, as a result of tamoxifen's "carryover" effect, duration trials require considerable follow-up before definitive results can be established.
  • Until more definitive data become available, adjuvant treatment with tamoxifen should be limited to 5 years outside the clinical trials setting.
  • Continued accrual of ER-positive patients to ongoing tamoxifen duration trials, including the Adjuvant Tamoxifen Treatment Offer More (aTTom) and Adjuvant Tamoxifen Longer Against Shorter (ATLAS) trials, is appropriate.
  • Alternatively, patients who remain disease free after 5 years of tamoxifen therapy should be encouraged to participate in trials testing crossover to other hormonal interventions, including selective ER modulators or aromatase inhibitors.
  • [MeSH-major] Antineoplastic Agents, Hormonal / administration & dosage. Antineoplastic Agents, Hormonal / therapeutic use. Breast Neoplasms / drug therapy. Tamoxifen / administration & dosage. Tamoxifen / therapeutic use
  • [MeSH-minor] Chemotherapy, Adjuvant / methods. Disease-Free Survival. Female. Follow-Up Studies. Humans. Neoplasm Metastasis. Neoplasms, Hormone-Dependent / drug therapy. Neoplasms, Hormone-Dependent / mortality. Postmenopause. Premenopause. Randomized Controlled Trials as Topic. Receptors, Estrogen / metabolism. Survival Rate. Time Factors

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11773293.001).
  • [ISSN] 1052-6773
  • [Journal-full-title] Journal of the National Cancer Institute. Monographs
  • [ISO-abbreviation] J. Natl. Cancer Inst. Monographs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Receptors, Estrogen; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down






Advertisement